Professor Humphrey Rang, President
Humphrey was a J H Burn research Fellow, at the Department of Pharmacology, Oxford, under the supervision of WDM Paton. His research interests are drug receptors, including the first successful receptor labelling studies, and kinetic analysis of ligand binding. Ion channels, channel block and synaptic mechanisms at the neuromuscular junction and autonomic ganglia. Pain, nociception and the identification of new targets for analgesic drugs. Humphrey has authored many research papers on these topics. Humphrey is also an author of Pharmacology (1987), now in its 7th Edition translated into 10 languages and winner of BMA Student Textbook Award (2007), and Drug Discovery and Development, winner of the Royal Society of Medicine Library Prize for Medical Book of the Year (2007).
Professor David Webb, President-Elect
David trained in medicine in London, started research training at the MRC Blood Pressure Unit in Glasgow, and completed research and clinical training in pharmacology & therapeutics in John Kelly‘s department at St George’s Hospital in London, working with Dr Joe Collier. His main interests are the pathophysiology and treatment of hypertension and chronic kidney disease, particularly focusing on endothelial function, and in the promotion of safe and effective prescribing. He is involved in running two Scottish translational medicine and therapeutics (TMAT) initiatives, supported by the Wellcome Trust and MRC.
Dr Robin Hiley, Honorary Treasurer
Robin trained under the supervision of Sir Arnold Burgen, first in Cambridge and then at the National Institute for Medical Research. He was a lecturer at the University of Liverpool before moving back to the University of Cambridge where he is now Reader in Vascular Pharmacology. His interests lie in the control of blood vessel tone by the endothelium and in the effects of lipid derivatives, such as the endocannabinoids, on cardiovascular function.
Professor Antony Galione, Co-Chair of CHOPT
Antony obtained a degree in Pharmacology from the University of Cambridge, and a PhD there under the supervision of Sir Michael Berridge. He has been at the Department of Pharmacology at the University of Oxford since 1991, and was elected to the Chair of Pharmacology in 2006 and has also been Head of Department since then. His research interests are in the field of calcium signalling, and in particular the role of calcium mobilizing messengers such as IP3, cyclic ADP-ribose and NAADP in receptor-effector coupling. He is a Wellcome Trust Senior Investigator and a Fellow of the Academy of Medical Sciences.
Professor Alyn Morice, Co-Chair of CHOPT
Professor Morice qualified at Cambridge University and after House jobs in London undertook research (MD) into the pharmacology of asthma at St Mary’s Hospital. As Clinical Lecturer at Addenbrooke’s Hospital Professor Morice developed his interest in cough, demonstrating cough hypersensitivity caused by ACE inhibitors. In 1989 Professor Morice was appointed as Senior Lecturer in Sheffield developing a Pulmonary Vascular service and the first UK Cough Clinic. In 1998 Professor Morice was appointed to the Foundation Chair in Respiratory Medicine in Hull University (now part of the Hull York Medical School). The Cough Clinic has become the largest centre within Europe with an international pattern of referral. Unique investigational strategies provide diagnosis and treatment advances which are incorporated into national and international guideline documents. Professor Morice has led the European Respiratory Society and British Thoracic Society Taskforces on Cough.
Professor Richard Green, Elected Trustee
Richard is currently Honorary Professor of Neuropharmacology at the University of Nottingham. His PhD was with Gerald Curzon and following two years at NIMH, Washington DC he joined David Grahame-Smith at the MRC Clinical Pharmacology Unit in Oxford, becoming Assistant Director in 1981. In 1986 he was appointed Director of the new Astra Neuroscience Research Unit in London, subsequently becoming Director, Global Discovery CNS & Pain Control for AstraZeneca. After retiring from AstraZeneca he has continued psychopharmacology research in Nottingham. He is a former President of the International Society for Serotonin Research and a President Emeritus of the British Pharmacological Society.
Dr Michael Seed, Elected Trustee
Mike trained as a pharmacologist at the University of Bath, and his PhD under the supervision of Ivor Williams. He joined the field of arthritis drug discovery, working on integrative arthritis and angiogenesis modelling at Hoechst and then Roussel. He continued his research into the modelling of angiogenesis, inflammation, immunity and arthritis at the William Harvey Research Institute, in collaboration with Biotech and a variety of drug targets. He has been lecturing on the Bart’s & the London MBBS and BMedSci courses, and is currently Reader in Pharmacology at the University of East London. Mike also serves on the BPS CHOPT Committee.
Dr Smita Price, Elected Trustee (Industry)
Smita is a neuropharmacologist with 20 years’ experience of working in the pharmaceutical industry. Smita obtained her BSc in Pharmacology at Cardiff University and gained her PhD in Physiology studying Movement disorders at Manchester University (supervised by Dr Paul Slater and Dr Alan Crossman). She spent 5 years as a Post-Doctoral fellow at the Institute of Psychiatry in London, specialising in epilepsy and schizophrenia. Smita then joined Merck Neuroscience Research centre in Harlow, where she gained over 15 years’ experience in CNS drug discovery and development. Smita is currently an independent pharmaceutical consultant.
Dr David Wood, Elected Trustee (Clinical)
David is a Consultant Physician and Clinical Toxicologist at Guy's and St Thomas' NHS Foundation Trust and King's Health Partners and an honorary senior lecture at King's College London. He studied medicine at the University of Bristol and his MD research and training in clinical pharmacology and therapeutics, clinical toxicology and general medicine in London. He has specialist clinical, research and academic interests in the epidemiology of use and acute toxicity ('harm') associated with the use of classical recreational drugs and novel psyschoactive substances ('legal highs'); he is an expert adviser to both the UK Advisory Council on the Misuse of Drugs (ACMD) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in these areas.
Professor Ann Daly, Co-opted Trustee
Ann is Professor of Pharmacogenetics at the Institute of Cellular Medicine, Newcastle University. After a PhD in Biochemical Pharmacology at Trinity College, Dublin and postdoctoral work at the University of Geneva, she joined the Newcastle University Pharmacogenetics Research Group. Her research interests include the pharmacogenetics of the human cytochromes P450 and genetic susceptibility to idiosyncratic adverse drug reactions.
Dr Christine Williams, Co-opted Trustee
Chris is an in vitro pharmacologist with over 17 years of experience in the pharmaceutical industry. She gained her PhD in Biochemistry at the University of Kent with Professor Philip Strange, where she studied the effects of co-expression of Dopamine receptors with different G-protein alpha subunits. Subsequently she joined Pfizer, where she worked in reagent development, high-throughput screening and SAR generating groups. Through this she gained a breadth of scientific, project, portfolio and business management experience across early stage drug discovery. She is passionate about the appropriate pharmacological validation of assays and the development of relevant screening cascades for use in drug discovery. After a year and a half working much more closely with patients, as a General Manager in East Kent Hospitals University Foundation Trust, Chris is now back in the pharmaceutical industry working at UCB.
David O Douglas, Trustee
David is a Chartered Accountant who has over 40 years experience with charities as a trustee, treasurer, adviser and auditor. Charities (including member societies) are being encouraged to include people with specialist experience in their Board of Trustees. David has had an involvement with the Society in various capacities over the last 30 years which we feel will be of benefit to us.